What is retatrutide, stated in both halves at once
Those two sentences have to be held together, and almost nothing written about this compound manages it. Sellers quote the first and go quiet about the second. Cautious writers reach for the sentence they use about everything else in this market, that there is no human evidence, and in this case that sentence is simply false.
The first half. Phase 2 results were published in the New England Journal of Medicine in 2023 by Jastreboff and colleagues. In adults with obesity, the trial reported mean weight reduction of roughly 24 percent at 48 weeks in the group receiving the highest amount studied, 12 mg weekly. That is a large effect for a weight management drug and it is not a preliminary signal from a dish or a mouse. It is a randomised trial in people, in a leading journal.
The second half. There is no marketing authorisation for it in the United States, the European Union, the United Kingdom or anywhere else. The Phase 3 programme, run under the TRIUMPH name, is still ongoing. Until a regulator reviews the completed evidence and grants a licence, no pharmacy can dispense it and no doctor, however qualified, can write you a prescription for it.
The gap here is regulatory, not evidential, and that makes it a different problem from almost everything else sold in this market.
Three receptors, and why a third one was added
The approved drugs that reshaped weight management act on the GLP-1 receptor, and a later one acts on GLP-1 and GIP together. This compound adds a third target, the glucagon receptor.
The reasoning is not obscure. GLP-1 signalling reduces appetite and slows stomach emptying. Adding GIP appeared to improve on that. Glucagon signalling is associated with increased energy expenditure and with effects on liver fat, so the hypothesis was that acting on all three would produce more weight loss than acting on two.
Glucagon is also the hormone that raises blood sugar, which is why combining it with agents that lower blood sugar is a balancing act rather than a simple addition, and why the trials watch metabolic measures closely. Naming the mechanism is easy. Establishing that the balance holds across a large population over years is what a Phase 3 programme is for, and that is exactly what has not finished.
The published trial, described accurately
Precision matters here, because both overstatement and understatement are common.
The trial was Phase 2. It enrolled adults with obesity, randomised them to different amounts or to placebo, escalated the amount gradually over months, and ran for 48 weeks. The headline figure is a mean at the highest amount studied. Individual participants did better and worse than that mean, as they always do.
A Phase 2 trial is designed to find out whether an effect exists and at roughly what amounts, not to settle how a drug behaves in a large and varied population over years. It uses selected participants who meet entry criteria and pass exclusions. It is not long enough to characterise harms that appear slowly or rarely. Everything about how this compound behaves in people who would never have been enrolled remains open.
None of that diminishes the result. It places it.
Approved nowhere means exactly that
It is worth spelling out because the consequences are practical rather than abstract.
There is no manufacturing standard that anyone is holding a seller to. There is no leaflet, because no regulator has compiled one. There is no approved use, so nobody has decided who this is for. There is no defined amount outside a trial protocol. There is no recall route if a batch is wrong. There is no reporting system that will record what happens to you. And there is no legitimate supply chain, which means the vial in circulation did not come from the company that ran the trial.
A clinic cannot fix any of that. This is the part people find hardest to believe, because they are used to a private consultation being a route around inconvenience. Here it is not. A telehealth service offering to prescribe this is not offering a shortcut through a queue. It is offering something that does not exist.
Who can legally supply this, and who cannot
The third row is the one most readers skip past and it is the most useful line on the page. There are approved medicines in this class that a doctor can lawfully prescribe today, with a licence, a leaflet, a known manufacturer and a reporting system behind them. Whether they suit any particular person is a clinical question. That they exist, and that this one does not, is the practical shape of the choice.
| Setting | Can they supply it | What they are actually offering | What you get with it |
|---|---|---|---|
| A trial site running the Phase 3 programme | Yes, to enrolled participants | The manufactured drug, under a protocol | Screening, monitoring, and a route if something goes wrong |
| A pharmacy, on prescription | No | Nothing. There is no licence to dispense against | Not applicable |
| A weight management clinic | No, not this compound | Approved medicines in the same class, which they can prescribe | The full protections of a licensed purchase |
| A telehealth service claiming otherwise | No | An unlicensed product, whatever the paperwork says | A consultation fee |
| A research chemical supplier | It sells it, labelled not for human use | An unverified vial | A disclaimer |
What a grey market vial is, next to what the trial used
The trial administered a product made by a pharmaceutical manufacturer to a defined standard, tested for identity, strength and sterility, and traceable to a batch.
What circulates outside that is powder from a supplier no regulator has inspected, sold with a statement that it is not for human consumption, to be dissolved by the buyer. Its identity rests on the seller's word. Its strength rests on the seller's word. Its sterility rests on the seller's word. Independent testing across this category has repeatedly found material that does not match its label, in both directions.
So a person copying a trial amount from the published paper is applying a precise figure to a substance of unknown concentration, without the escalation supervision the trial used, and without anyone watching. The precision of the number is doing a lot of reassuring work that the vial cannot support.
Why this compound creates more pressure than the others
Most unapproved compounds are easy to argue about because the evidence is thin. Someone wanting them is chasing a hope. Here the hope has a published trial attached to it, and that changes the psychology completely.
People have read the headlines. They know somebody who has struggled with weight for decades. They can see a result that would change their life, and they can also see that there is no legal way to obtain it and possibly years to wait. That is an intense and entirely understandable pressure, and it is the reason the grey market for this compound is larger and more determined than for anything else discussed here.
Pretending the trial result is weak would be a lie, and it would not persuade anyone who has read the coverage. The accurate position is harder and more respectful: the evidence is real, the route is not, and the gap between a trial arm and a vial from an unregulated supplier is where the actual risk lives.